Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dexamethasone phosphate
Drug ID BADD_D00624
Description Not Available
Indications and Usage Not Available
Marketing Status Not Available
ATC Code Not Available
DrugBank ID Not Available
KEGG ID D07802
MeSH ID C004180
PubChem ID 9400
TTD Drug ID D0NA8U
NDC Product Code Not Available
UNII 2BP70L44PR
Synonyms dexamethasone 21-phosphate | dexamethasone phosphate | dexamethasone 21-phosphate, monosodium salt, (11beta,16alpha)-isomer | dexamethasone sodium phosphate | dexamethasonedisodium phosphate | dexamethasone phosphate disodium salt | Solu- Decadron | Spersadex | Spersadox | dexamethasone 21-phosphate, (6alpha,11beta,16alpha)-isomer | dexamethasone 21-phosphate, disodium salt, (11beta,16alpha)-isomer | dexamethasone 21-phosphate, disodium salt, (6alpha,11beta,16alpha)-isomer | Decadron phosphate | dexamethasone 21-phosphate, sodium salt, (11beta,16alpha)-isomer | dexamethasone 21-phosphate, copper (+2) salt (2:3), (11beta,16alpha)-isomer
Chemical Information
Molecular Formula C22H30FO8P
CAS Registry Number 312-93-6
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)COP(=O)(O)O)O)C)O)F)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Increased appetite08.01.09.027; 14.03.01.003---
Increased insulin requirement05.06.01.006; 14.06.01.006---
Increased tendency to bruise01.01.03.005; 23.06.01.009; 24.07.06.012---
Inflammatory bowel disease07.08.01.016---
Insomnia17.15.03.002; 19.02.01.002--
Intracranial pressure increased17.07.02.002---
Intraocular pressure increased13.07.04.002---
Irritability08.01.03.011; 19.04.02.013--
Large intestine perforation07.04.06.005; 12.02.03.005--
Lethargy08.01.01.008; 17.02.04.003; 19.04.04.004--
Leukocytosis01.02.01.002--
Leukoderma23.05.02.001---
Malaise08.01.01.003--
Mania19.16.02.002--
Menstruation irregular05.05.01.008; 21.01.01.005--
Muscle atrophy15.05.03.003; 17.05.03.004---
Muscle disorder15.05.03.014---
Muscular weakness15.05.06.001; 17.05.03.005--
Myalgia15.05.02.001--
Myocardial infarction02.02.02.007; 24.04.04.009--
Myocardial rupture02.04.02.002; 12.01.11.002---
Myopathy15.05.05.001---
Nausea07.01.07.001--
Necrosis ischaemic24.04.02.018---
Neuropathy peripheral17.09.03.003---
Nitrogen balance negative13.13.01.010---
Oesophageal candidiasis07.19.06.001; 11.03.03.008---
Oesophagitis07.08.05.001--
Opportunistic infection11.01.08.007---
Optic neuritis06.04.08.002; 10.02.01.097; 17.04.05.001---
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages